Showing results (21-30 of 43) with videos related to
Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|March 3, 2018
Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research ConsortiumDavid R Spigel, John D Hainsworth, Dianna L Shipley, et al.Clinical Genitourinary Cancer|February 15, 2008
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trialJohn D Hainsworth, David R Spigel, Jeffrey A Sosman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancerKathy D Miller, Thomas J Saphner, David M Waterhouse, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2011
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancerDavid R Spigel, John D Hainsworth, Dianna L Shipley, et al.Investigational New Drugs|December 2, 2010
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancerStefan Madajewicz, David M Waterhouse, Paul S Ritch, et al.Cancer|April 13, 2018
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signaturesDavid R Spigel, Howard A Burris, F Anthony Greco, et al.Investigational New Drugs|March 12, 2017
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancersJennifer R Diamond, Barbara Goff, Martin D Forster, et al.JCO Oncology Practice|May 13, 2020
Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology SurveyDavid M Waterhouse, R Donald Harvey, Patricia Hurley, et al.Lung Cancer (Amsterdam, Netherlands)|March 25, 2018
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC)John D Hainsworth, David M Waterhouse, Kent C Shih, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancerDavid R Spigel, Howard A Burris, F Anthony Greco, et al.Pageof 5